Johnson & Johnson Overview
JNJ market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
JNJ price chart · 1M
- O
- 267.00
- H
- 269.53
- L
- 265.65
- C
- 269.53
- Vol
- 39,103.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $267.00
- Previous Close
- $272.45
- Day High
- $269.53
- Day Low
- $265.65
- 52 Week High
- $281.86
- 52 Week Low
- $181.19
- 7 Day Return
- -1.36%
- 30 Day Return
- +4.27%
- 90 Day Return
- +3.52%
- 1 Year Return
- +47.41%
- Daily Notional Volume
- $10.5M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 41.97 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $11.03 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 16.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $185.12 – $282.02 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $285.31 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $675.4B · P/B 6.13 · P/S 6.80.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
FDA Grants Accelerated Approval for RYBREVANT FASPRO in Head and Neck Squamous Cell CarcinomaFiscal.ai ·
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobenewswire Inc ·
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs WellZacks Investment Research ·